Market Closed -
Nasdaq
01:30:00 30/04/2024 am IST
|
5-day change
|
1st Jan Change
|
21.28
USD
|
+1.04%
|
|
+1.53%
|
-1.53%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
238.3
|
1,048
|
1,184
|
1,733
|
1,833
|
1,808
|
-
|
-
|
Enterprise Value (EV)
1 |
178.5
|
754.9
|
981.6
|
1,249
|
1,255
|
1,517
|
1,586
|
1,703
|
P/E ratio
|
-4.77
x
|
-11.9
x
|
45.6
x
|
-10.3
x
|
-7.25
x
|
-5.66
x
|
-7.55
x
|
-9.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
157
x
|
691
x
|
8.47
x
|
-
|
-
|
58.4
x
|
15.6
x
|
7.98
x
|
EV / Revenue
|
118
x
|
498
x
|
7.03
x
|
-
|
-
|
49
x
|
13.6
x
|
7.51
x
|
EV / EBITDA
|
-3.07
x
|
-10.6
x
|
36.5
x
|
-8.05
x
|
-5.13
x
|
-4.4
x
|
-5.66
x
|
-11
x
|
EV / FCF
|
-3.53
x
|
-10.6
x
|
33.8
x
|
-9.34
x
|
-7.82
x
|
-5.89
x
|
-9.18
x
|
-17.9
x
|
FCF Yield
|
-28.4%
|
-9.44%
|
2.95%
|
-10.7%
|
-12.8%
|
-17%
|
-10.9%
|
-5.6%
|
Price to Book
|
7.54
x
|
4.22
x
|
-
|
3.71
x
|
2.74
x
|
3.48
x
|
6.12
x
|
8.7
x
|
Nbr of stocks (in thousands)
|
27,140
|
47,119
|
54,074
|
68,100
|
84,810
|
84,980
|
-
|
-
|
Reference price
2 |
8.780
|
22.24
|
21.89
|
25.45
|
21.61
|
21.28
|
21.28
|
21.28
|
Announcement Date
|
03/03/20
|
08/03/21
|
01/03/22
|
28/02/23
|
27/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1.517
|
1.517
|
139.7
|
-
|
-
|
30.99
|
116.2
|
226.6
|
EBITDA
1 |
-58.23
|
-71.33
|
26.91
|
-155.1
|
-244.7
|
-345.1
|
-280.4
|
-154.3
|
EBIT
1 |
-57.54
|
-71.42
|
26.22
|
-151.8
|
-230
|
-333.9
|
-268.5
|
-190.4
|
Operating Margin
|
-3,792.95%
|
-4,708.17%
|
18.77%
|
-
|
-
|
-1,077.49%
|
-231.1%
|
-84.02%
|
Earnings before Tax (EBT)
1 |
-56.05
|
-73.16
|
24.93
|
-149.3
|
-209.4
|
-325.2
|
-262.6
|
-180.4
|
Net income
1 |
-56.05
|
-77.06
|
24.93
|
-149.3
|
-209.4
|
-314.2
|
-256.1
|
-204
|
Net margin
|
-3,694.59%
|
-5,080.03%
|
17.84%
|
-
|
-
|
-1,013.97%
|
-220.44%
|
-90.03%
|
EPS
2 |
-1.840
|
-1.870
|
0.4800
|
-2.460
|
-2.980
|
-3.763
|
-2.818
|
-2.193
|
Free Cash Flow
1 |
-50.61
|
-71.26
|
29
|
-133.7
|
-160.6
|
-257.5
|
-172.7
|
-95.33
|
FCF margin
|
-3,336.32%
|
-4,697.43%
|
20.76%
|
-
|
-
|
-831.03%
|
-148.63%
|
-42.07%
|
FCF Conversion (EBITDA)
|
-
|
-
|
107.79%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
116.35%
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
03/03/20
|
08/03/21
|
01/03/22
|
28/02/23
|
27/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
12.38
|
126.6
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
7.074
|
25.1
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-81.36
|
-82.93
|
-88.33
|
-94.12
|
-55.85
|
EBIT
1 |
-20.03
|
95.75
|
-36.86
|
-37.72
|
-35.14
|
-42.03
|
-46.02
|
-49.68
|
-56.36
|
-77.9
|
-84.02
|
-88.49
|
-87.28
|
-71.65
|
Operating Margin
|
-161.87%
|
75.65%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,233.77%
|
-285.49%
|
Earnings before Tax (EBT)
1 |
-20.64
|
96.2
|
-37.17
|
-37.57
|
-35.4
|
-39.19
|
-41.13
|
-44.62
|
-51.15
|
-72.47
|
-80.34
|
-84.41
|
-80.46
|
-77.95
|
Net income
1 |
-20.64
|
96.2
|
-37.17
|
-37.57
|
-35.4
|
-39.19
|
-41.13
|
-44.62
|
-51.15
|
-72.47
|
-79.65
|
-83.8
|
-81.18
|
-66.9
|
Net margin
|
-166.78%
|
76%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,147.62%
|
-266.57%
|
EPS
2 |
-0.4000
|
1.810
|
-0.6300
|
-0.6200
|
-0.5800
|
-0.6200
|
-0.5900
|
-0.6400
|
-0.7300
|
-1.000
|
-0.9738
|
-1.025
|
-0.9825
|
-0.7962
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
15/11/21
|
01/03/22
|
09/05/22
|
08/08/22
|
03/11/22
|
28/02/23
|
08/05/23
|
03/08/23
|
02/11/23
|
27/02/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
59.8
|
293
|
202
|
484
|
578
|
291
|
223
|
106
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-50.6
|
-71.3
|
29
|
-134
|
-161
|
-258
|
-173
|
-95.3
|
ROE (net income / shareholders' equity)
|
-132%
|
-54.3%
|
7.55%
|
-34.1%
|
-41%
|
-60.5%
|
-74.7%
|
-52.4%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-31.5%
|
-37.7%
|
-55.1%
|
-61.5%
|
-64%
|
Assets
1 |
-
|
-
|
-
|
473.4
|
555.1
|
570.4
|
416.1
|
318.7
|
Book Value Per Share
2 |
1.160
|
5.270
|
-
|
6.860
|
7.880
|
6.110
|
3.480
|
2.450
|
Cash Flow per Share
2 |
-
|
-
|
-
|
-
|
-2.280
|
-3.080
|
-0.7600
|
-
|
Capex
1 |
-
|
-
|
0.13
|
-
|
-
|
1.7
|
1.7
|
1.7
|
Capex / Sales
|
-
|
-
|
0.09%
|
-
|
-
|
5.49%
|
1.46%
|
0.75%
|
Announcement Date
|
03/03/20
|
08/03/21
|
01/03/22
|
28/02/23
|
27/02/24
|
-
|
-
|
-
|
Last Close Price
21.28
USD Average target price
34.92
USD Spread / Average Target +64.08% Consensus |
1st Jan change
|
Capi.
|
---|
| -1.53% | 1.81B | | +1.77% | 42.86B | | +46.34% | 41.36B | | +12.24% | 42.74B | | -8.83% | 27.68B | | +7.44% | 25.15B | | -23.01% | 18.63B | | +30.56% | 12.37B | | -1.82% | 11.92B | | +8.35% | 11.21B |
Other Biotechnology & Medical Research
|